Autifony Therapeutics Limited
http://www.autifonytherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Autifony Therapeutics Limited
Jazz’s CNS Pipeline Demonstrates Transformation
With a first-in-class cannabis-derived treatment for epilepsy, a market-leading treatment for sleep disorders and now a foray into movement disorders, Jazz’s CNS pipeline is strong.
In Vivo’s Deals Of The Year: Cast Your Vote!
It is time for In Vivo's 16th annual Deals of the Year contest. We've selected 12 nominees across three categories – Top M&A, Top Alliance and Top Financing – and you get to pick the winners.
Autifony Tunes In To Jazz With Neurology-Focused Deal
Deal Snapshot: The two companies will collaborate on drugs targeting two ion channels in neurological disorders, with Autifony receiving upfront and milestone payments up to $770.5m.
Deal Watch: NewAmsterdam To Take On Amgen’s Stalled CETP Inhibitor
New company licenses obicetrapib from Amgen after previous companies’ setbacks in CETP class and works with FDA on a Phase III protocol. BMS buys protein-engineering specialist Forbius.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice